COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis (NAMASTE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03622658
Recruitment Status : Completed
First Posted : August 9, 2018
Last Update Posted : April 17, 2020
Iqvia Pty Ltd
Innovate UK
Information provided by (Responsible Party):
Izana Bioscience Ltd.

Brief Summary:
The study will assess the effect of namilumab, a GM-CSF inhibitor, on the clinical response in subjects with axial spondyloarthritis. Subjects will receive treatment with either namilumab or placebo

Condition or disease Intervention/treatment Phase
Axial Spondyloarthritis Biological: Placebo Biological: Namilumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Proof of Concept, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety/Tolerability and Efficacy of 4 Subcutaneous Injections of Namilumab (150 mg) Given Over 10 Weeks in Subjects With Moderate-to-severely Active Axial Spondyloarthritis Including Those Previously Exposed to Anti-TNF Therapy
Actual Study Start Date : August 8, 2018
Actual Primary Completion Date : February 4, 2020
Actual Study Completion Date : February 4, 2020

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeksx
Biological: Placebo
Placebo solution for subcutaneous injection.

Experimental: Namilumab
Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeksx
Biological: Namilumab
Namilumab solution for subcutaneous injection

Primary Outcome Measures :
  1. Efficacy of Namilumab [ Time Frame: Week 12 ]

    Number of subjects with 20% improvement in Assessment in Ankylosing Spondylitis Assessment (ASAS20) at the Week 12 visit.

    clinical response at 12 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 and ≤ 75 years of age
  • Diagnosis of axSpA by an appropriately qualified physician and classified using ASAS criteria ≥ 3 months prior to Baseline
  • Bath Ankylosing Spondylitis Disease Activity Index score ≥ 4 and spinal pain score ≥ 40, at screening and Baseline.
  • MRI evidence of active axSpA ≤ 6 (ideally ≤ 3) months prior to randomisation using ASAS criteria.
  • Stable NSAID use prior to study entry
  • Stable use of MTX, sulfasalazine orleflunomide to study entry
  • Stable oral corticosteroid dose prior to study entry.
  • Capable of giving signed informed consent
  • Inadequately responded to or experienced intolerance to previous treatment with an anti-TNF agent (some subjects)

Exclusion Criteria:

  • Current diagnosis of axSpA with a BASDAI > 4 but no evidence of inflammation on MRI
  • Discontinued biologic therapy < 8 weeks prior to Baseline.
  • Previous or current use of oral corticosteroid as defined in protocol
  • Received intra-articular or i.v. corticosteroids prior to or during Screening
  • Received anti-IL-17A or anti IL12/23 therapy
  • Received cyclosporine, tacrolimus or mycophenolate mofetil prior to Baseline
  • Previously received stem cell transplantation
  • Infection(s) requiring treatment with i.v. anti-infectives or oral anti-infectives prior to Baseline
  • Abnormal screening laboratory and other analyses
  • Receipt of any live vaccine within 2 weeks prior to randomisation, or will require live vaccination during study participation
  • Evidence of current or prior dysplasia or history of malignancy
  • Has had any uncontrolled and/or clinically significant illness, hospitalisation, or any surgical procedure requiring general anaesthesia prior to Screening, or any planned surgical procedure within 6 months after randomisation
  • Known current or previous interstitial lung disease
  • Positive pregnancy test at Screening (serum) or Baseline (urine)
  • Female subjects who are breastfeeding or considering becoming pregnant during the study
  • Considered by the Investigator to be an unsuitable candidate for the study
  • Received any investigational agent or procedure within 30 days or 5 half-lives prior to Baseline
  • Related to or a dependent of the site staff, or a member of the site staff

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03622658

Layout table for location information
United Kingdom
Royal United Hospitals Bath
Bath, United Kingdom
University Hospital Birmingham
Birmingham, United Kingdom
University Hospital Coventry and Warwickshire
Coventry, United Kingdom
Northwick Park Hospital
London, United Kingdom
Whipps Cross Hospital
London, United Kingdom
Norfolk and Norwich University Hospital
Norwich, United Kingdom
Oxford University Hospital
Oxford, United Kingdom
Royal Berkshire Hospital
Reading, United Kingdom
Haywood Hospital
Stoke-on-Trent, United Kingdom
Sponsors and Collaborators
Izana Bioscience Ltd.
Iqvia Pty Ltd
Innovate UK
Layout table for additonal information
Responsible Party: Izana Bioscience Ltd. Identifier: NCT03622658    
Other Study ID Numbers: IZN-101
First Posted: August 9, 2018    Key Record Dates
Last Update Posted: April 17, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Joint Diseases